A Study of LY2523355 in Patients With Solid Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to examine a recommended dose for subsequent phase trial(s), by the observation of the safety and toxicity profiles of LY2523355 in patients with advanced and/or metastatic cancer. The secondary objectives are to study the pharmacokinetics and antitumor effect.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies

NCT07173595

Relapsed or Refractory Hematologic Malignancies

RECRUITING PHASE1

A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma

NCT04977193

Advanced Gastric Adenocarcinoma

UNKNOWN EARLY_PHASE1

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL

NCT06641024

Acute Lymphoblastic Leukemia, in Relapse Refractory Acute Lymphoblastic Leukemia

NOT_YET_RECRUITING PHASE1

Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors

NCT07330895

CD19+ Relapse/Refractory B-ALL

NOT_YET_RECRUITING EARLY_PHASE1

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

NCT03593109

Lymphoma, B-Cell

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY2523355

Group Type EXPERIMENTAL

LY2523355

Intervention Type DRUG

Days 1, 2, and 3 in a cycle that consists of 21-days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY2523355

Days 1, 2, and 3 in a cycle that consists of 21-days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histological and/or cytological evidence of solid tumors
* A diagnosis of advanced and/or metastatic solid tumors
* Patients who are refractory to standard therapy or for which no proven effective therapy exists
* Written informed consent
* Appropriate bone marrow, hepatic and renal functions
* ECOG PS =\< 1

Exclusion Criteria

* Have serious preexisting complication
* Have active infection which requires intravenous antibiotics
* Have symptomatic central nervous system metastases
* Have current acute or chronic leukemia
* Have had an autologous or allogenic hematopoietic stem cell transplantation
* Have active multiple cancers

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No